Claims

1. A NOX inhibitor, or a pharmaceutically acceptable salt thereof, for use in the treatment of Alport syndrome.

2. A NOX inhibitor for use as claimed in Claim 1, wherein the NOX inhibitor is a NOX4 inhibitor, a NOX4/1 inhibitor or a NOX1 inhibitor, or a pharmaceutically acceptable salt thereof.

3. A NOX inhibitor for use as claimed in Claim 1 or Claim 2, wherein the NOX inhibitor is a pyrazolo pyridine NOX4 or NOX4/1 inhibitor, a pyrazolinedione NOX4 or NOX4/1 inhibitor, an amidothiazole NOX1 or NOX4/1 inhibitor, or an indole NOX4/1 inhibitor, or a pharmaceutically acceptable salt thereof.

4. A NOX inhibitor for use as claimed in any one of Claims 1 to 3, wherein the NOX inhibitor is a 2,5-disubstituted benzoxazole or a benzothiazole NOX4 inhibitor, or a pharmaceutically acceptable salt thereof.

5. A NOX inhibitor for use as claimed in any one of Claims 1 to 3, wherein the NOX inhibitor is a NOX inhibitor according to Formula (I):



(I)

wherein:

G^1 is selected from the group consisting of:

H;

optionally substituted alkyl, such as aminocarbonyl alkyl (e.g. phenylacetamide);

optionally substituted C_3-C_8-cycloalkyl alkyl;

optionally substituted heterocycloalkyl alkyl;

aryl alkyl, such as phenyl alkyl, for example phenyl methyl or 3-methyl phenyl methyl;

substituted aryl alkyl, such as substituted phenyl alkyl, for example substituted phenyl methyl (e.g. 4-fluorobenzyl, 2-chlorobenzyl, 4-chlorobenzyl, 4-methyl benzyl, or 4-bromobenzyl);

heteroaryl alkyl; and

substituted heteroaryl alkyl, such as substituted pyridine alkyl, for example pyridine-2-yl methyl;

G^2 is selected from the group consisting of:

H;

optionally substituted alkyl;

optionally substituted alkenyl;

optionally substituted alkynyl;

optionally substituted aryl, such as phenyl (e.g. 4-fluorophenyl, 4-methoxyphenyl, 4-nitrophenyl, 2-chlorophenyl, 2-methyl phenyl, 4-(trifluoromethyl) phenyl, 4-(trifluoromethoxy) phenyl, 2,5-difluorophenyl, or 2-methoxyphenyl);

optionally substituted alkyl aryl;

optionally substituted aryl alkyl;

heteroaryl, such as benzothiazolyl, or pyridinyl;

substituted heteroaryl, such as substituted benzothiazolyl (e.g. 1,3-benzothiazol-2-yl), or substituted pyridinyl (e.g. pyridin-2-yl);

optionally substituted alkyl heteroaryl;

optionally substituted heteroaryl alkyl;

optionally substituted alkenyl aryl;

optionally substituted aryl alkenyl;

optionally substituted alkenyl heteroaryl;

optionally substituted heteroaryl alkenyl;

optionally substituted C_3-C_8-cycloalkyl;

optionally substituted heterocycloalkyl;

optionally substituted alkyl C_3-C_8-cycloalkyl;

optionally substituted C_3-C_8-cycloalkyl alky;

optionally substituted alkyl heterocycloalkyl; and

optionally substituted heterocycloalkyl alkyl;

G^3 is selected from the group consisting of:

H;

optionally substituted alkyl, such as optionally substituted methyl or optionally substituted ethyl;

optionally substituted alkenyl;

optionally substituted alkynyl;

optionally substituted aryl, such as optionally substituted phenyl;

optionally substituted alkyl aryl;

optionally substituted aryl alkyl;
optionally substituted heteroaryl;
optionally substituted alkyl heteroaryl;
optionally substituted heteroaryl alkyl;
optionally substituted alkenyl aryl;
optionally substituted aryl alkenyl;
optionally substituted alkenyl heteroaryl;
optionally substituted heteroaryl alkenyl;
optionally substituted C_3-C_8-cycloalkyl;
optionally substituted heterocycloalkyl;
optionally substituted alkyl C_3-C_8-cycloalkyl;
optionally substituted C_3-C_8-cycloalkyl alkyl;
optionally substituted alkyl heterocycloalkyl; and
optionally substituted heterocycloalkyl alkyl;

G^4 is selected from the group consisting of:

H;
optionally substituted alkyl, such as optionally substituted pentyl (e.g., isopentyl);
optionally substituted heteroalkyl;
optionally substituted alkoxy, such as optionally substituted methoxy; (e.g. 2-methoxyethyl);
optionally substituted alkenyl;
optionally substituted alkynyl;
optionally substituted aryl;
optionally substituted alkyl aryl;
aryl alkyl, such as benzyl or phenyl ethyl (e.g., 2-phenyl ethyl);
substituted aryl alkyl such as substituted benzyl (e.g. benzoic acid methyl) or substituted phenyl ethyl (e.g. 4-methoxyphenyl ethyl);
optionally substituted heteroaryl;
optionally substituted alkyl heteroaryl;
optionally substituted heteroaryl alkyl, such as optionally substituted thiophenyl alkyl (such as optionally substituted thiophenyl methyl, for example thiophen-2-yl methyl), optionally substituted imidazolyl alkyl (such as optionally substituted imidazolyl ethyl, for example imidazol-4-yl ethyl), optionally substituted indolyl alkyl (such as optionally substituted indolyl ethyl, for example indol-3-yl ethyl), optionally substituted furanyl alkyl (such as optionally substituted furanyl methyl, for example furan-2-yl methyl), optionally substituted benzodioxolyl alkyl (such as optionally substituted benzodioxolyl methyl, for example 1,3-benzodioxol-5-yl methyl), or optionally substituted pyridinyl methyl (such as pyridine-3-yl methyl or pyridin-2-yl methyl);

optionally substituted alkenyl aryl;
optionally substituted aryl alkenyl;
optionally substituted alkenyl heteroaryl;
optionally substituted heteroaryl alkenyl;
optionally substituted C_3-C_8-cycloalkyl;
heterocycloalkyl, such as morpholinyl (e.g., 5-morpholin-4-yl), piperazinyl (e.g. 4-methyl piperazinyl), or piperidinyl (e.g. 4-methylbenzyl)piperidin-4-yl);
substituted heterocycloalkyl, such as substituted morpholinyl (e.g. 5-morpholin-4-yl), substituted piperazinyl (e.g. 4-methyl piperazinyl), or substituted piperidinyl (e.g. 4-methylbenzyl)piperidin-4-yl);
optionally substituted alkyl C_3-C_8-cycloalkyl;
optionally substituted C_3-C_8-cycloalkyl alkyl;
optionally substituted alkyl heterocycloalkyl;
heterocycloalkyl alkyl, such as morpholinyl alkyl (for example, morpholinyl ethyl, or morpholinyl propyl, in particular 2-morpholin-4-yl-ethyl, or 3-(morpholin-4-yl) propyl), piperazinyl alkyl (such as piperazinyl ethyl, for example 2-(4-acetylpiperazin-1-yl) ethyl, or 2-(4-hexanoyl piperazin-1-yl) ethyl), or pyrrolidinyl alkyl (such as pyrrolidinyl propyl, for example 3-(2-oxopyrrolidin-l-yl) propyl), or tetrahydro furanyl alkyl (such as tetrahydrofuranyl methyl, for example tetrahydrofuran-2-yl methyl); and
substituted heterocycloalkyl alkyl such as substituted morpholinyl alkyl (for example substituted morpholinyl ethyl, or substituted morpholinyl propyl, in particular substituted 2-morpholin-4-yl-ethyl, or substituted 3-(morpholin-4-yl) propyl), substituted piperazinyl alkyl (such as substituted piperazinyl ethyl, for example substituted 2-(4-acetylpiperazin-1-yl) ethyl or substituted 2-(4-hexanoyl piperazin-1-yl) ethyl), or substituted pyrrolidinyl alkyl (such as substituted pyrrolidinyl propyl, for example substituted 3-(2-oxopyrrolidin-l-yl) propyl), or substituted tetrahydro furanyl alkyl (such as substituted tetrahydrofuranyl methyl, for example substituted tetrahydrofuran-2-yl methyl);

G^5 is selected from the group consisting of:
H;
optionally substituted alkyl;
optionally substituted alkenyl;
optionally substituted alkynyl;
optionally substituted aryl;
optionally substituted alkyl aryl;
optionally substituted aryl alkyl;
optionally substituted heteroaryl;
optionally substituted alkyl heteroaryl;

optionally substituted heteroaryl alkyl;
optionally substituted alkenyl aryl;
optionally substituted aryl alkenyl;
optionally substituted alkenyl heteroaryl;
optionally substituted heteroaryl alkenyl;
optionally substituted C_3-C_8-cycloalkyl;
optionally substituted heterocycloalkyl;
optionally substituted alkyl C_3-C_8-cycloalkyl;
optionally substituted C_3-C_8-cycloalkyl alkyl;
optionally substituted alkyl heterocycloalkyl; and
optionally substituted heterocycloalkyl alkyl;

as well as pharmaceutically acceptable salts thereof.

6. A NOX inhibitor for use as claimed in any one of Claims 1 to 3, wherein the NOX inhibitor is a NOX inhibitor according to Formula (II):



(II)

wherein:

Ar^1 is selected from the list consisting of:

phenyl;
phenyl substituted by a halogen, such as chloro (for example wherein Ar^1 is 2-chlorophenyl); and
phenyl substituted by an alkoxy, such as methoxy

G^1 and G^5 are H;

G^3 is selected from the list consisting of:

optionally substituted C_1-C_6 alkyl, such as optionally substituted methyl;
phenyl;
phenyl substituted by halogen, amino, alkyl amino, or alkoxy, for example wherein the phenyl is 3-chlorophenyl, 4-chlorophenyl, 2-fluorophenyl, 3 -fluorophenyl, 4-fluorophenyl, 4-chloro-2-fluorophenyl, 5-chloro-2-fluorophenyl, 3-dimethylaminophenyl, 2- tri-methyl amino phenyl, 3 -methyl amino phenyl, 3 -amino phenyl, or 4-methoxy phenyl;

G^4 is selected from the list consisting of:

H;

C_1-C_6 alkyl, such as methyl,

substituted C_1-C_6 alkyl, such as substituted methyl, optionally wherein the C_1-C_6 alkyl is substituted by an alkoxy, such as wherein the substituted C_1-C_6 alkyl is methoxy ethyl, for example 2-methoxy ethyl;

heteroaryl C_1-C_6 alkyl, such as pyridinyl C_1-C_6 alkyl (for example pyridinyl methyl, in particular pyridinyl-2-yl methyl, pyridinyl-3-yl methyl, 6-methoxypyridin-3-yl methyl, 2-methoxypyridin-4-yl methyl), or pyrazinyl C_1-C_6 alky, such as pyrazinyl-2-ylmethyl;

substituted heteroaryl C_1-C_6 alkyl, such as substituted pyridinyl C_1-C_6 alkyl (for example substituted pyridinyl methyl, in particular substituted pyridinyl-2-yl methyl, substituted pyridinyl-3-yl methyl, substituted 6-methoxypyridin-3-yl methyl, substituted 2-methoxypyridin-4-yl methyl), or substituted pyrazinyl C_1-C_6 alky, such as substituted pyrazinyl-2-ylmethyl;

alkoxy C_1-C_6 alkyl, such as methoxy ethyl (for example 2-methoxy ethyl); and

substituted C_1-C_6 alkyl, such as substituted methoxy ethyl (for example substituted 2-methoxy ethyl)

or G^3 and G^4 form together an optionally substituted 7-membered heterocycloalkyl ring comprising two nitrogen atoms, and where the two nitrogens are attached through a optionally substituted C_1-C_3 alkyl moiety,

as well as tautomers, geometrical isomers, optically active forms and pharmaceutically acceptable salts thereof.

7. A NOX inhibitor for use as claimed in any one of Claims 1 to 3, wherein the NOX inhibitor is a NOX inhibitor according to Formula (III):



(III)

wherein:

Ar^1, G^1 and G^5 are as defined in Claim 5 or Claim 6;

G^6 is selected from the group consisting of:

C_1-C_6 alkyl;

substituted C_1-C_6 alkyl;

aryl C_1-C_6 alkyl, such as benzyl;

substituted aryl C_1-C_6 alkyl, such as substituted phenyl C_1-C_6 alkyl, for example 2-chlorobenzyl, 3-chlorobenzyl, 4-chlorobenzyl, 2-methoxybenzyl, 3-methoxybenzyl, 4-methoxybenzyl);

heteroaryl C_1-C_6 alkyl, such as pyridinyl C_1-C_6 alkyl, for example pyridinyl methyl (such as pyridinyl-2-yl methyl, or pyridinyl-3-yl methyl), or furanyl C_1-C_6 alkyl, for example furanyl methyl (such as furan-3-yl methyl);

substituted heteroaryl C_1-C_6 alkyl, such as substituted pyridinyl C_1-C_6 alkyl, for example substituted pyridinyl methyl (such as substituted pyridinyl-2-yl methyl, or substituted pyridinyl-3-yl methyl), or substituted furanyl C_1-C_6 alkyl, for example substituted furanyl methyl (such as substituted furan-3-yl methyl);

as well as tautomers, geometrical isomers, optically active forms and pharmaceutically acceptable salts thereof.

8. A NOX inhibitor for use as claimed in any one of Claims 1 to 3, wherein the NOX inhibitor is a NOX inhibitor according to Formula (IV):



(IV)

wherein:

A^1, A^2 and A^3 are independently selected from the list consisting of:

hydrogen;

halogen;

CN;

CF_3;

CHF_2;

optionally substituted C_1-C_6 alkyl;

optionally substituted C_3-C_8 cycloalkyl;
optionally substituted heteroalkyl;
optionally substituted heterocycloalkyl;
optionally substituted alkoxy;
optionally substituted amino;
optionally substituted carboxy; and
optionally substituted alkoxycarbonyl; and

R^i is selected from the group consisting of:
hydrogen;
halogen;
CN;
CF_3;
CHF_2;
optionally substituted C_1-C_6 alkyl;
optionally substituted C_3-C_8 cycloalkyl;
optionally substituted heteroalkyl;
optionally substituted heterocycloalkyl; and
optionally substituted carboxy;

R^{ii} is selected from the list consisting of:
hydrogen;
optionally substituted C_1-C_6 alkyl;
C_3-C_8 cycloalkyl;
optionally substituted halo C_1-C_6 alkyl;
optionally substituted halo C_3-C_8 cycloalkyl;
optionally substituted aryl C_1-C_6 alkyl;
optionally substituted heteroaryl C_1-C_6 alkyl;
optionally substituted heteroalkyl;
optionally substituted heterocycloalkyl;
substituted heterocycloalkyl;
optionally substituted heterocycloalkyl C_1-C_6 alkyl;
optionally substituted hydroxy C_1-C_6 alkyl;
optionally substituted alkoxy C_1-C_6 alkyl;
optionally substituted alkoxycarbonyl C_1-C_6 alkyl;
optionally substituted aminocarbonyl C_1-C_6 alkyl;
optionally substituted aryl C_3-C_8 cycloalkyl;
optionally substituted heteroaryl C_3-C_8 cycloalkyl;
optionally substituted alkoxy C_3- C_8 cycloalkyl;
optionally substituted amino C_3-C_8 cycloalkyl; and
optionally substituted halo C_3-C_8 cycloalkyl;

Ar^3 is selected from:



;

R^1 and R^4 are independently selected from the list consisting of:

hydrogen;

halogen;

CN;

CF_3;

CHF_2;

NH_2;

optionally substituted C_1-C_6 alkyl;

optionally substituted C_3-C_8 cycloalkyl;

alkoxy;

amino;

optionally substituted heterocycloalkyl;

carboxy;

optionally substituted alkoxy C_1-C_6 alkyl;

optionally substituted alkoxy C_3-C_8 cycloalkyl;

optionally substituted amino C_1-C_6 alkyl;

optionally substituted amino C_3-C_8 cycloalkyl;

optionally substituted amino heterocycloalkyl C_1-C_6 alkyl;

optionally substituted carboxy C_3-C_8 cycloalkyl; and

optionally substituted aminocarbonyl C_1-C_6 alkyl;

R^2 is selected from the list consisting of:

hydrogen;

halogen;

CF_3;

CHF_2;

NH_2;

optionally substituted C_1-C_6 alkyl;

optionally substituted C_3-C_8 cycloalkyl;

optionally substituted alkoxy;

amino;

optionally substituted heterocycloalkyl;

carboxy;

optionally substituted alkoxy C_1-C_6 alkyl;

optionally substituted alkoxy C_3-C_8 cycloalkyl;

optionally substituted amino C_1-C_6 alkyl;

optionally substituted amino C_3-C_8 cycloalkyl;

optionally substituted amino heterocycloalkyl C_1-C_6 alkyl;

optionally substituted C_3-C_8 carboxy cycloalkyl; and

optionally substituted aminocarbonyl C_1-C_6 alkyl;

R^3 is selected from the list consisting of:

hydrogen;

halogen;

CF_3;

CHF_2;

NH_2;

optionally substituted C_1-C_6 alkyl;

optionally substituted C_3-C_8 cycloalkyl;

optionally substituted alkoxy;

amino;

optionally substituted heterocycloalkyl;

carboxy;

optionally substituted alkoxy C_1-C_6 alkyl;

optionally substituted alkoxy C_3-C_8 cycloalkyl;

optionally substituted amino C_1-C_6 alkyl;

optionally substituted amino C_3-C_8 cycloalkyl;

optionally substituted amino heterocycloalkyl C_1-C_6 alkyl;

optionally substituted C_3-C_8 carboxy cycloalkyl; and

optionally substituted aminocarbonyl C_1-C_6 alkyl;

R^5 is selected from the group consisting of:

hydrogen;

halogen;

CF_3;

CHF_2;

NH_2;

optionally substituted C_1-C_6 alkyl;

optionally substituted C_3-C_8 cycloalkyl;

optionally substituted alkoxy;

amino;

optionally substituted heterocycloalkyl;

carboxy;

optionally substituted alkoxy C_1-C_6 alkyl;

optionally substituted alkoxy C_3-C_8 cycloalkyl;

optionally substituted amino C_1-C_6 alkyl;

optionally substituted amino C_3-C_8 cycloalkyl;

optionally substituted amino heterocycloalkyl C_1-C_6 alkyl;

optionally substituted C_3-C_8 carboxy cycloalkyl; and

optionally substituted aminocarbonyl C_1-C_6 alkyl,

wherein when one from R^1, R^2, R^3 and R^4 is not H, the other from this group are H or any of R^1, R^2, R^3, R^4 and R^5 can be linked together to form an optionally substituted bicyclic heteroaryl;

Ar^3 is also selected from an optionally substituted bicyclic heteroaryl, in particular from the group consisting of:



wherein R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12} and R^{13} are each independently selected from the list consisting of:

hydrogen;

halogen;

hydroxy;

CN;

CF_3;

CHF_2;

NH_2;

alkoxy;

amino;

carboxy;

aminocarbonyl;

alkoxy carbonyl;

optionally substituted C_1-C_6 alkyl;

optionally substituted C_3-C_8 cycloalkyl;

optionally substituted halo alkyl;
optionally substituted heteroalkyl;
optionally substituted heterocycloalkyl;
optionally substituted aryl;
optionally substituted heteroaryl;
optionally substituted C_3-C_8 cycloalkyl C_1-C_6 alkyl;
optionally substituted heterocycloalkyl C_1-C_6 alkyl;
optionally substituted aryl C_1-C_6 alkyl;
optionally substituted heteroaryl C_1-C_6 alkyl;
optionally substituted alkoxy C_1- C_6 alkyl;
optionally substituted amino C_1-C_6 alkyl;
optionally substituted carboxy C_1- C_6 alkyl;
optionally substituted aminocarbonyl C_1-C_6 alkyl;
optionally substituted heterocycloalkyl C_3-C_8 cycloalkyl;
optionally substituted aryl C_3-C_8 cycloalkyl;
optionally substituted heteroaryl C_3-C_8 cycloalkyl;
optionally substituted alkoxy C_3-C_8 cycloalkyl;
optionally substituted amino C_3-C_8 cycloalkyl;
optionally substituted carboxy C_3-C_8 cycloalkyl;
optionally substituted aminocarbonyl C_3-C_8 cycloalkyl;
acylamino;
ureido;
sulfonyl; and
sulfonylamino;

R^{14} is selected from the list consisting of:
hydrogen;
aminocarbonyl;
alkoxy carbonyl;
optionally substituted C_1-C_6 alkyl;
optionally substituted C_3-C_8 cycloalkyl;
optionally substituted halo alkyl;
optionally substituted heteroalkyl;
optionally substituted heterocycloalkyl;
optionally substituted aryl;
optionally substituted heteroaryl;
optionally substituted C_3-C_8 cycloalkyl C_1-C_6 alkyl;
optionally substituted heterocycloalkyl C_1-C_6 alkyl;
optionally substituted aryl C_1-C_6 alkyl;
optionally substituted heteroaryl C_1-C_6 alkyl;

optionally substituted alkoxy C_1-C_6 alkyl;

optionally substituted amino C_1-C_6 alkyl,

carboxy C_1-C_6 alkyl;

optionally substituted aminocarbonyl C_1-C_6 alkyl;

optionally substituted heterocycloalkyl C_3-C_8 cycloalkyl;

aryl C_3-C_8 cycloalkyl;

optionally substituted heteroaryl C_3-C_8 cycloalkyl;

optionally substituted alkoxy C_3-C_8 cycloalkyl;

optionally substituted amino C_3-C_8 cycloalkyl;

optionally substituted carboxy C_3-C_8 cycloalkyl, and

optionally substituted aminocarbonyl C_3-C_8 cycloalkyl;

Ar^2 is selected from the following group:





















;

wherein R^{15}, R^{16} and R^{19} are independently selected from the list consisting of:

hydrogen;

halogen;

hydroxy;

CN;

CF_3;

CHF_2;

NH_2;

alkoxy;

amino;

carboxy;

aminocarbonyl;
alkoxy carbonyl;
optionally substituted C_1-C_6 alkyl;
optionally substituted C_3-C_8 cycloalkyl;
optionally substituted alkenyl;
alkynyl;
optionally substituted haloalkyl;
optionally substituted heteroalkyl;
optionally substituted heterocycloalkyl;
optionally substituted aryl;
optionally substituted heteroaryl;
optionally substituted C_3-C_8 cycloalkyl C_1-C_6 alkyl;
optionally substituted heterocycloalkyl C_1-C_6 alkyl;
optionally substituted aryl C_1-C_6 alkyl;
optionally substituted heteroaryl C_1-C_6 alkyl;
optionally substituted alkoxy C_1- C_6 alkyl;
optionally substituted amino C_1-C_6 alkyl;
optionally substituted carboxy C_1- C_6 alkyl;
aminocarbonyl C_1-C_6 alkyl;
optionally substituted heterocycloalkyl C_3-C_8 cycloalkyl;
optionally substituted aryl C_3-C_8 cycloalkyl;
optionally substituted heteroaryl C_3-C_8 cycloalkyl;
optionally substituted alkoxy C_3-C_8 cycloalkyl;
optionally substituted amino C_3-C_8 cycloalkyl;
optionally substituted carboxy C_3-C_8 cycloalkyl;
optionally substituted aminocarbonyl C_3-C_8 cycloalkyl;
acylamino;
ureido; and
sulfonyl; or

wherein R^{15}, R^{16} and R^{19} may further be selected from the following groups:



wherein y, w, z and t are independently:

an integer ranging from 1 to 3;

wherein h is:

an integer ranging from 0 to 3;

wherein n is:

an integer ranging from 0 to 4;

wherein G is selected from the list consisting of:

N-R^{23};

O;

S; and

SO_2;

wherein J is selected from the list consisting of:

C(B)n; and

N-R^{23};

wherein L is selected from the list consisting of:

C-(B)n;

N-R^{23};

O;

S; and

SO_2;

wherein R^{23} is selected from the list consisting of:

hydrogen;

aminocarbonyl;

alkoxy carbonyl;

optionally substituted C_1-C_6 alkyl;

optionally substituted C_3-C_8 cycloalkyl;

optionally substituted halo alkyl;

optionally substituted heteroalkyl;

optionally substituted heterocycloalkyl;
optionally substituted aryl;
optionally substituted heteroaryl;
C_3-C_8 cycloalkyl C_1-C_6 alkyl;
optionally substituted heterocycloalkyl C_1-C_6 alkyl;
optionally substituted aryl C_1-C_6 alkyl;
optionally substituted heteroaryl C_1-C_6 alkyl;
alkoxy C_1-C_6 alkyl;
optionally substituted amino C_1-C_6 alkyl;
optionally substituted carboxy C_1-C_6 alkyl;
optionally substituted aminocarbonyl C_1-C_6 alkyl;
optionally substituted heterocycloalkyl C_3-C_8 cycloalkyl;
optionally substituted aryl C_3-C_8 cycloalkyl;
optionally substituted heteroaryl C_3-C_8 cycloalkyl;
optionally substituted alkoxy C_3-C_8 cycloalkyl;
optionally substituted amino C_3-C_8 cycloalkyl;
optionally substituted carboxy C_3-C_8 cycloalkyl;
optionally substituted aminocarbonyl C_3-C_8 cycloalkyl; and
aminosulfonyl;

wherein B is selected from the group consisting of:
hydrogen;
halogen;
hydroxy;
CN;
CF_3;
CHF_2;
NH_2;
alkoxy;
amino;
carboxy;
aminocarbonyl;
alkoxy carbonyl;
optionally substituted C_1-C_6 alkyl;
optionally substituted C_3-C_8 cycloalkyl;
optionally substituted halo alkyl;
optionally substituted heteroalkyl;
optionally substituted heterocycloalkyl;
optionally substituted aryl;
optionally substituted heteroaryl;

optionally substituted C_3-C_8 cycloalkyl C_1-C_6 alkyl;
optionally substituted heterocycloalkyl C_1-C_6 alkyl;
optionally substituted aryl C_1-C_6 alkyl;
optionally substituted heteroaryl C_1-C_6 alkyl;
optionally substituted alkoxy C_1-C_6 alkyl;
optionally substituted amino C_1-C_6 alkyl;
optionally substituted carboxy C_1-C_6 alkyl;
aminocarbonyl C_1-C_6 alkyl;
optionally substituted heterocycloalkyl C_3-C_8 cycloalkyl;
optionally substituted aryl C_3-C_8 cycloalkyl;
optionally substituted heteroaryl C_3-C_8 cycloalkyl;
optionally substituted alkoxy C_3-C_8 cycloalkyl;
optionally substituted amino C_3-C_8 cycloalkyl;
optionally substituted carboxy C_3-C_8 cycloalkyl;
optionally substituted aminocarbonyl C_3-C_8 cycloalkyl;
acylamino;
ureido;
sulfonyl; and
sulfonylamino;

wherein R^{17} and R^{18} are independently selected from the list consisting of:
hydrogen;
halogen;
CN;
CF_3;
CHF_2;
alkoxy;
amino;
optionally substituted C_1-C_6 alkyl;
optionally substituted C_3-C_8 cycloalkyl;
optionally substituted halo alkyl;
optionally substituted heteroalkyl;
optionally substituted heterocycloalkyl;
optionally substituted C_3-C_8 cycloalkyl C_1-C_6 alkyl;
optionally substituted heterocycloalkyl C_1-C_6 alkyl;
optionally substituted alkoxy C_1-C_6 alkyl;
optionally substituted amino C_1-C_6 alkyl;
optionally substituted heterocycloalkyl C_3-C_8 cycloalkyl;
optionally substituted alkoxy C_3-C_8 cycloalkyl;
optionally substituted amino C_3-C_8 cycloalkyl;

acylamino;
ureido;
sulfonyl;
aminosulfonyl; and
sulfonylamino;

wherein R^{20} and R^{22} are independently selected from the list consisting of:

hydrogen;
halogen;
CN;
CF_3;
CHF_2;
alkoxy;
amino;
optionally substituted C_1-C_6 alkyl;
optionally substituted C_3-C_8 cycloalkyl;
optionally substituted haloalkyl;
optionally substituted heteroalkyl;
optionally substituted heterocycloalkyl;
optionally substituted C_3-C_8 cycloalkyl C_1-C_6 alkyl;
optionally substituted heterocycloalkyl C_1-C_6 alkyl;
optionally substituted alkoxy C_1-C_6 alkyl;
optionally substituted amino C_1-C_6 alkyl;
optionally substituted heterocycloalkyl C_3-C_8 cycloalkyl;
optionally substituted alkoxy C_3-C_8 cycloalkyl;
and optionally substituted amino C_3-C_8 cycloalkyl;

wherein R^{21} is selected from the list consisting of:

hydrogen;
aminocarbonyl;
alkoxy carbonyl;
optionally substituted C_1-C_6 alkyl;
optionally substituted C_3-C_8 cycloalkyl;
optionally substituted halo alkyl;
optionally substituted heteroalkyl;
heterocycloalkyl;
optionally substituted aryl;
optionally substituted heteroaryl;
optionally substituted C_3-C_8 cycloalkyl C_1-C_6 alkyl;
optionally substituted heterocycloalkyl C_1-C_6 alkyl aryl C_1-C_6 alkyl;
optionally substituted heteroaryl C_1-C_6 alkyl;

optionally substituted alkoxy C_1-C_6 alkyl;
optionally substituted amino C_1-C_6 alkyl;
optionally substituted carboxy C_1-C_6 alkyl;
optionally substituted aminocarbonyl C_1-C_6 alkyl;
optionally substituted heterocycloalkyl C_3-C_8 cycloalkyl;
optionally substituted aryl C_3-C_8 cycloalkyl;
optionally substituted heteroaryl C_3-C_8 cycloalkyl;
optionally substituted alkoxy C_3-C_8 cycloalkyl;
optionally substituted amino C_3-C_8 cycloalkyl;
optionally substituted carboxy C_3-C_8 cycloalkyl; and
optionally substituted aminocarbonyl C_3-C_8 cycloalkyl;

wherein R^{15} and R^{16} can be linked together to form an optionally substituted bicyclic heteroaryl having the following formula:



wherein X, Y and Z are each independently selected from the list consisting of:
$C(R^{24}R^{25})$;
$CH_2C(R^{24}R^{25})$;
C(=O);
O; and
N-R^{26};

wherein R^{24} and R^{25} are each independently selected from the list consisting of:
hydrogen;
halogen;
hydroxy;
CN;
CF_3;
CHF_2;
NH_2;
alkoxy;
amino;
carboxy;
aminocarbonyl;

alkoxy carbonyl;
optionally substituted C_1-C_6 alkyl;
optionally substituted C_3-C_8 cycloalkyl;
optionally substituted halo alkyl;
optionally substituted heteroalkyl;
optionally substituted heterocycloalkyl;
optionally substituted aryl;
optionally substituted heteroaryl;
optionally substituted C_3-C_8 cycloalkyl C_1-C_6 alkyl;
optionally substituted heterocycloalkyl C_1-C_6 alkyl;
optionally substituted aryl C_1-C_6 alkyl;
optionally substituted heteroaryl C_1-C_6 alkyl;
optionally substituted alkoxy C_1-C_6 alkyl;
optionally substituted amino C_1-C_6 alkyl;
optionally substituted carboxy C_1-C_6 alkyl;
optionally substituted aminocarbonyl C_1-C_6 alkyl;
optionally substituted heterocycloalkyl C_3-C_8 cycloalkyl;
optionally substituted aryl C_3-C_8 cycloalkyl;
optionally substituted heteroaryl C_3-C_8 cycloalkyl;
optionally substituted alkoxy C_3-C_8 cycloalkyl;
optionally substituted amino C_3-C_8 cycloalkyl;
optionally substituted carboxy C_3-C_8 cycloalkyl;
optionally substituted aminocarbonyl C_3-C_8 cycloalkyl;
acylamino;
ureido;
sulfonyl; and
sulfonylamino;

wherein R^{24} and R^{25} can be linked together to form an optionally substituted C_3-C_8 cycloalkyl or an optionally substituted heterocycloalkyl;

wherein R^{26} is selected from the group consisting of:
hydrogen;
aminocarbonyl;
alkoxy carbonyl;
optionally substituted C_1-C_6 alkyl;
optionally substituted C_3-C_8 cycloalkyl;
optionally substituted halo alkyl;
optionally substituted heteroalkyl;
optionally substituted heterocycloalkyl;
optionally substituted aryl;

optionally substituted heteroaryl;
optionally substituted C_3-C_8 cycloalkyl C_1-C_6 alkyl;
optionally substituted heterocycloalkyl C_1-C_6 alkyl;
optionally substituted aryl C_1-C_6 alkyl;
optionally substituted heteroaryl C_1-C_6 alkyl;
optionally substituted alkoxy C_1-C_6 alkyl;
amino C_1-C_6 alkyl;
optionally substituted carboxy C_1-C_6 alkyl;
optionally substituted aminocarbonyl C_1-C_6 alkyl;
optionally substituted heterocycloalkyl C_3-C_8 cycloalkyl;
optionally substituted aryl C_3-C_8 cycloalkyl;
optionally substituted heteroaryl C_3-C_8 cycloalkyl;
optionally substituted alkoxy C_3-C_8 cycloalkyl;
optionally substituted amino C_3-C_8 cycloalkyl;
optionally substituted carboxy C_3-C_8 cycloalkyl;
optionally substituted aminocarbonyl C_3-C_8 cycloalkyl; and
aminosulfonyl;

wherein R^{15} and R^{19} can be linked together to form an optionally substituted bicyclic heteroaryl;

wherein R^{15} and R^{21} can be linked together to form an optionally substituted bicyclic heteroaryl;

wherein R^{17} and R^{21} can be linked together to form an optionally substituted bicyclic heteroaryl;

wherein R^{20} and R^{21} can be linked together to form an optionally substituted bicyclic heteroaryl;

as well as tautomers, geometrical isomers, optically active forms, and pharmaceutically acceptable salts thereof.

9. A NOX inhibitor for use as claimed in any one of Claims 1 to 3, wherein the NOX inhibitor is a NOX inhibitor according to Formula (V):



(V)

wherein:

X^i is selected from the list consisting of CR^{27} and N;

Y^i is selected from the list consisting of CH and N;

A_4 is selected from the list consisting of:

$-OCHR^{31}-$;

$-NR^{30}-CHR^{31}-$;

$-CH_2NR^{30}-$; and

$-CH_2-O-$;

wherein R^{27} is selected from the list consisting of:

H;

halogen;

and optionally substituted C_1-C_6 alkyl;

wherein R^{28} is selected from the list consisting of:

H;

halogen (e.g. chloro, fluoro);

optionally substituted alkoxy such as optionally substituted methoxy (e.g. methoxy, (tetrahydro-2H-pyran-4-yl)methoxy, piperidin-4-ylmethoxy) or optionally substituted ethoxy (e.g. 2-(dimethylamino)ethoxy, 2-hydroxy ethoxy, 1 -phenyl ethoxy, 2-methoxy ethoxy);

optionally substituted alkoxy C_1-C_6 alkyl;

optionally substituted C_1-C_6 alkyl such as optionally substituted methyl;

optionally substituted amino such as optionally substituted C_1-C_6 alkyl amino (e.g. methyl amino, tetrahydro-2H-pyran-4-yl)methyl)amino, (1-methylpiperidin-4-yl)methyl)amino, di-methyl amino, optionally substituted ethyl amino such as 2-morpholino ethyl amino or 2-(dimethylamino) ethyl amino or methoxy ethyl amino, optionally substituted methyl amino such as 1 -methyl-1H-imidazol-4-yl methyl amino or 2-hydroxyethyl)amino, optionally substituted propyl amino such as dimethylamino propyl amino);

optionally substituted heterocycloalkyl such as optionally substituted piperazine (e.g. methylpiperazin-1-yl);

optionally substituted C_1-C_6 alkyl heterocycloalkyl such as optionally substituted C_1-C_6 alkyl piperazine (e.g. methylpiperazin-1-yl);

optionally substituted amino C_1-C_6 alkyl;

optionally substituted alkoxy C_1-C_6 alkyl;

$-O-R^{34}$; and

$-NR^{35}R^{36}$;

wherein R^{29} is a group of formula $-(CHR^{32})n-A_5$; or

R^{29} forms with the moiety CHR^{31} from A_4 an optionally substituted ring selected from optionally substituted aryl such as an optionally substituted phenyl (e.g. phenyl or phenyl substituted by halogen such as fluoro phenyl substituted by alkoxy such as methoxy) and optionally substituted heteroaryl such as optionally substituted 1,3-dihydro-1H-indenyl (e.g. 1-(dimethylamino)-2,3-dihydro-1H-inden-2-yl, 2,3-dihydro-1H-inden-2-yl, 2,3-dihydro-1H-inden-1-yl) or optionally substituted 6,7-dihydro-5H-cyclopenta pyridinyl (e.g. 6,7-dihydro-5H-cyclopenta[*b*]pyridin-5-yl, 2-methylpyridin-3-yl, 5-methylpyridin-2-yl) or optionally substituted 1,2,3,4-tetrahydronaphthalenyl (e.g. 1 ,2,3,4-tetrahydronaphthalen-1-yl) or optionally substituted 2,3-dihydrobenzofuranyl (e.g. 2,3-dihydrobenzofuran-3-yl, 2,3- dihydro-1H-inden-1-yl) or optionally substituted thiadiazolyl (e.g. 1,3,4-thiadiazol-2-yl) or optionally substituted isoxazolyl (e.g. 5-methylisoxazol-3-yl) or optionally substituted pyrazolyl (e.g. 1 -methyl-1H-pyrazol-3-yl) or optionally substituted imidazolyl (e.g. 1- methyl-1H-imidazol-2yl);

or

R^{29} forms with the moiety NR^{30} from A_4 an optionally substituted ring selected from the list consisting of optionally substituted aryl and optionally substituted heteroaryl such as optionally substituted isoindolinyl (e.g. isoindolin-2-yl, 1H-indol-1-yl);

wherein n is an integer from 0 to 4 (such as 0, 1 , 2, 3 or 4);

wherein R^{30} is selected from H and optionally substituted alkyl, such as optionally substituted methyl;

wherein A_5 is an optionally substituted ring selected from optionally substituted aryl such as optionally substituted phenyl (e.g. methoxy phenyl, fluoro phenyl, chloro phenyl), optionally substituted heteroaryl such as optionally substituted pyridine (e.g. pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, 2-methyl pyridin-3-yl, 5-methyl pyridin-2-yl) or optionally substituted pyrazolyl (e.g. 1 ,3-dimethyl-1H-pyrazol-5-yl, 1 -methyl-1H-pyrazol-3-y) or optionally substituted thiadiazolyl (e.g. 1,3,4-thiadiazol-2-yl) or optionally substituted imidazolyl (e.g. 1H-imidazol-4-yl, 1 -methyl-1H-imidazol-2-yl, 1-methyl-1H-imidazol-5-yl) or optionally substituted 1,2,4-triazolyl (e.g. 1-methyl-1H-1,2,4-triazol-5-yl) or optionally substituted isoxazolyl (e.g. 1-cyclopropylisoxazol-3-yl) or optionally substituted oxadiazolyl (e.g. 5-methyl-1,2,4-oxadiazol-3-yl) or optionally substituted pyrimidinyl (e.g. pyrimidinyl-2-yl);

wherein R^{31} is selected from the list consisting of:

H;

optionally substituted C_1-C_6 alkyl such as optionally substituted methyl (e.g. methoxy methyl, 3,3-difluoropyrrolidin-1-yl methyl, 4-methylpiperazin-1-yl methyl, hydroxyl methyl) or optionally substituted ethyl or optionally substituted

propyl (e.g. methyl, hydroxy methyl, hydroxy ethyl, 2-propanolyl, hydroxyl isopropyl);

optionally substituted amino C_1-C_6 alkyl such as optionally substituted amino methyl (e.g. dimethylamino methyl, methylamino methyl);

optionally substituted alkoxy C_1-C_6 alkyl;

optionally substituted heterocycloalkyl C_1-C_6 alkyl such as optionally substituted heterocycloalkyl methyl for example optionally substituted pyrrolidine C_1-C_6 alkyl (e.g. 3,3- difluoropyrrolidin-1-yl methyl) or substituted piperazine C_1-C_6 alkyl (e.g. 4- methylpiperazin-1-yl methyl) or heterocycloalkyl ethyl for example optionally substituted morpholino C_1-C_6 alkyl (e.g. morpholino methyl, morpholino ethyl) or optionally substituted pyrrolidine C_1-C_6 alkyl (e.g. pyrrolidine methyl, pyrrolidine ethyl);

optionally substituted aminocarbonyl (e.g. dimethyl aminocarbonyl);

optionally substituted C_2-C_8 cycloalkyl such as optionally substituted cyclopropyl; and

optionally substituted amino C_1-C_6 alkyl such as optionally substituted amino ethyl (e.g. di-methyl amino ethyl) or optionally substituted amino methyl (e.g. di-methyl amino methyl);

wherein R^{32} is selected from the list consisting of:

H;

optionally substituted C_1-C_6 alkyl such as optionally substituted methyl;

optionally substituted amino;

optionally substituted C_1-C_6 alkyl amino (e.g. dimethyl amino); and

hydroxy; and

wherein R^{32} groups are independently selected for each repeating unit (CHR^{32});

wherein R^{33} is selected from the list consisting of:

H;

halogen (e.g. fluoro); and

optionally substituted C1-C_6 alkyl such as methyl;

wherein R^{34} is selected from the group consisting of:

H;

optionally substituted C_1-C_6 alkyl such as optionally substituted methyl or optionally substituted ethyl (e.g. methoxy ethyl, 2- (dimethylamino)ethyl, hydroxy ethyl);

optionally substituted amino C_1-C_6 alkyl;

optionally substituted heterocycloalkyl;

optionally substituted C_2-C_8 cycloalkyl;

optionally substituted heterocycloalkyl C_1-C_6 alkyl such as optionally substituted heterocycloalkyl methyl, for example optionally substituted tetrahydropyran C_1-C_6

alkyl (e.g. tetrahydro-2H-pyran-4-yl) or optionally substituted piperidine alkyl (e.g. 1-methylpiperidin-4-yl);

optionally substituted C_2-C_8 cycloalkyl C_1-C_6 alkyl;

optionally substituted alkoxy;

optionally substituted amino C_1-C_6 alkyl such optionally substituted amino ethyl (e.g. 2- (dimethylamino)ethyl);

optionally substituted aryl C_1-C_6 alkyl; and

optionally substituted heteroaryl C_1-C_6 alkyl;

wherein R^{35} and R^{36} are independently selected from the list consisting of:

H;

optionally substituted C_1-C6 alkyl such as optionally substituted methyl (e.g. 1-methyl-1H-imidazol-4-yl)methyl)) or optionally substituted ethyl (e.g. 2-methoxy ethyl);

optionally substituted amino C_1-C_6 alkyl such as optionally substituted amino ethyl (e.g. dimethyl amino ethyl) or such as optionally substituted amino propyl (e.g. dimethylamino)propyl);

optionally substituted heterocycloalkyl such as optionally substituted piperidine (e.g. 1-methylpiperidin);

optionally substituted C_2-C_8 cycloalkyl;

optionally substituted heterocycloalkyl C_1-C_6 alkyl such as optionally substituted heterocycloalkyl ethyl for example optionally substituted morpholino C_1-C_6 alkyl (e.g. 2-morpholino ethyl) or optionally substituted heterocycloalkyl methyl for example optionally substituted tetrahydrofuran C_1-C_6 alkyl (e.g. tetrahydro-2H-pyran-4-yl methyl) or piperidine C_1-C_6 alkyl (e.g. 1-methylpiperidin-4-yl) methyl or optionally substituted imidazolyl C_1-C_6 alkyl (e.g. 1- methyl-1H-imidazol-4-yl)methyl)optionally substituted C_2-C_8 cycloalkyl C_1-C_6 alkyl;

optionally substituted alkoxy;

optionally substituted alkoxy C_1-C_6 alkyl such as optionally substituted alkoxy ethyl (e.g. 2-methoxy ethyl);

optionally substituted aryl C_1-C_6 alkyl; and

optionally substituted heteroaryl C_1-C_6 alkyl such as heteroaryl C_1-C_6 alkyl methyl, for example optionally substituted imidazolyl C_1-C_6 alkyl (e.g. 1-methyl-1H-imidazol-4-yl methyl), optionally substituted amino C_1-C_6 alkyl such optionally substituted amino ethyl or optionally substituted amino propyl (e.g. 2-(dimethylamino)ethyl, 2- (dimethylamino)propyl)); as well as tautomers, geometrical isomers, optically active forms, pharmaceutically acceptable salts and pharmaceutically active derivative thereof.

10. A NOX inhibitor for use as claimed in any one of Claims 1 to 3, wherein the NOX inhibitor is selected from the group consisting of:

2-(2-chlorophenyl)-4-methyl-5-(pyridin-2-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
4-(2-fluoro-4-methoxyphenyl)-2-(2-methoxyphenyl)-5-(pyridin-3-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
(R)-3-methoxy-4-(2-morpholino-1-phenylethoxy)-N-(5-(pyridin-4-yl)-1,3,4-thiadiazol-2-yl)benzamide;
10-benzyl-2-(2-chlorophenyl)-2,3,8,9,10,11--hexahydro-1H-pyrazolo[4',3':3,4] pyrido[1,2-a][1,4]diazepine-1,5(7H)-dione;
(S)-3-methoxy-4-(1-phenylethoxy)-N-(5-(pyridin-4-yl)-1,3,4-thiadiazol-2-yl) benzamide;
(R)-4-(2-hydroxy-1-phenylethoxy)-3-methoxy-N-(5-(pyridin-4-yl)-1,3,4-thiadiazol-2- yl)benzamide; and
(R)-4-(2-(dimethylamino)- 1 -phenylethoxy)-3 -methoxy-N-(5 -(pyridin-4-yl)-1,3,4- thiadiazol-2-yl)benzamide.

11. A NOX inhibitor for use as claimed in Claim 8, wherein the NOX inhibitor is selected from the group consisting of:
5-(2-methoxypyridin-4-yl)-2-(2-methylpyridin-4-yl)-1H-indole;
2,5-bis(2-methylpyridin-4-yl)-1H-indole;
4-(2-(2-methylpyridin-4-yl)-1H-indol-5-yl)pyridin-2-amine;
5-(5-fluoropyridin-3-yl)-2-(2-methylpyridin-4-yl)-1H-indole;
5-(5-chloropyridin-3-yl)-2-(2-methylpyridin-4-yl)-1H-indole;
5-(5-isopropoxypyridin-3-yl)-2-(2-methylpyridin-4-yl)-1H-indole;
N,N-dimethyl-5-(2-(2-methylpyridin-4-yl)-1H-indol-5-yl)pyridin-3-amine;
5-(6-methylpyridin-3-yl)-2-(2-methylpyridin-4-yl)-1H-indole;
2-(2-methylpyridin-4-yl)-5-(pyrimidin-5-yl)-1H-indole;
2-methyl-5-(2-(2-methylpyridin-4-yl)-1H-indol-5-yl)-1H-benzo[d]imidazole;
2-(2-(azetidin-1-yl)pyridin-4-yl)-5-(5-methoxypyridin-3-yl)-1H-indole;
5-(5-methoxypyridin-3-yl)-2-(2-methoxypyridin-4-yl)-1H-indole;
2-(2,6-dimethylpyridin-4-yl)-5-(5-methoxypyridin-3-yl)-1H-indole;
5-(5-methoxypyridin-3-yl)-2-(2-methylpyrimidin-4-yl)-1H-indole;
5-(5-methoxypyridin-3-yl)-2-(1-methyl-1H-imidazol-5-yl)-1H-indole;
4-(5-(5-methoxypyridin-3-yl)-1H-indol-2-yl)-2-methylthiazole;
2-(2-cyclopropylpyridin-4-yl)-5-(5-methoxypyridin-3-yl)-1H-indole;

1-(4-(5-(5-methoxypyridin-3-yl)-1H-indol-2-yl)pyridin-2-yl)azetidin-3-ol;
1-(4-(5-(5-methoxypyridin-3-yl)-1H-indol-2-yl)pyridin-2-yl)-6-oxa-1-azaspiro[3.3] heptane;
2-(2-(4,4-difluoropiperidin-1-yl)pyridin-4-yl)-5-(5-methoxypyridin-3-yl)-1H-indole;
4-(4-(5-(5-methoxypyridin-3-yl)-1H-indol-2-yl)pyridin-2-yl)morpholine;
2-(5-fluoropyridin-3-yl)-5-(5-methoxypyridin-3-yl)-1H-indole;
5-(5-methoxypyridin-3-yl)-2-(6-methoxypyridin-3-yl)-1H-indole;
4-(5-(5-(5-methoxypyridin-3-yl)-1H-indol-2-yl)pyridin-2-yl)morpholine;
5-(5-methoxypyridin-3-yl)-2-(6-(oxetan-3-yl)pyridin-3-yl)-1H-indole;
1-(5-(5-(5-methoxypyridin-3-yl)-1H-indol-2-yl)pyridin-2-yl)-6-oxa-1-azaspiro[3.3] heptane;
N,N-dimethyl-5-(5-(2-methylpyridin-4-yl)-1H-indol-2-yl)pyridin-2-amine;
4-(5-(5-methoxypyridin-3-yl)-1H-indol-2-yl)-N,N-dimethylpyridin-2-amine;
N,N-dimethyl-4-(5-(quinolin-4-yl)-1H-indol-2-yl)pyridin-2-amine;
1-(5-(6-chloro-5-(5-methoxypyridin-3-yl)-1H-indol-2-yl)pyridin-2-yl)-6-oxa-1-azaspiro[3.3]heptane;
1-(4-(6-chloro-5-(5-methoxypyridin-3-yl)-1H-indol-2-yl)pyridin-2-yl)-6-oxa-1-azaspiro[3.3]heptane;
1-(4-(6-chloro-5-(2-methylpyridin-4-yl)-1H-indol-2-yl)pyridin-2-yl)-6-oxa-1-azaspiro [3.3]heptane;
6-(5-(6-chloro-5-(5-methoxypyridin-3-yl)-1H-indol-2-yl)pyridin-2-yl)-2-oxa-6-azaspiro[3.3]heptane;
2-(5-(6-chloro-5-(5-methoxypyridin-3-yl)-1H-indol-2-yl)pyridin-2-yl)-7-oxa-2-azaspiro [3.5]nonane;
1-(5-(6-chloro-5-(5-methoxypyridin-3-yl)-1H-indol-2-yl)pyridin-2-yl)-3-methylazetidin- 3-ol;
6-chloro-2-(6-(3,3-difluoroazetidin-1-yl)pyridin-3-yl)-5-(5-methoxypyridin-3-yl)-1H-indole;
1-(5-(6-chloro-5-(5-methoxypyridin-3-yl)-1H-indol-2-yl)pyridin-2-yl)azetidine-3-carboxylic acid;
1-(5-(6-chloro-5-(5-methoxypyridin-3-yl)-1H-indol-2-yl)pyridin-2-yl)azetidine-3-carboxamide;
(1-(5-(6-chloro-5-(5-methoxypyridin-3-yl)-1H-indol-2-yl)pyridin-2-yl)azetidin-3-yl) methanol;
6-chloro-5-(5-methoxypyridin-3-yl)-2-(6-(3-methoxypyrrolidin-1-yl)pyridin-3-yl)-1H-indole;
N-(1-(5-(6-chloro-5-(5-methoxypyridin-3-yl)-1H-indol-2-yl)pyridin-2-yl)pyrrolidin-3-yl) methanesulfonamide;

(1-(5-(6-chloro-5-(5-methoxypyridin-3-yl)-1H-indol-2-yl)pyridin-2-yl)pyrrolidin-2-yl) methanol;
1-(5-(6-chloro-5-(5-methoxypyridin-3-yl)-1H-indol-2-yl)pyridin-2-yl)-5-(hydroxymethyl) pyrrolidin-2-one;
4-(5-(6-chloro-5-(5-methoxypyridin-3-yl)-1H-indol-2-yl)-3-fluoropyridin-2-yl) morpholine;
6-chloro-5-(5-methoxypyridin-3-yl)-2-(6-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-3-yl)-1H-indole;
6-chloro-2-(6-(4-ethylpiperazin-1-yl)pyridin-3-yl)-5-(5-methoxypyridin-3-yl)-1H-indole 4-(5-(6-chloro-5-(5-methoxypyridin-3-yl)-1H-indol-2-yl)pyridin-2-yl)thiomorpholine 1,1-dioxide;
6-chloro-2-(6-(4,4-difluoropiperidin-1-yl)pyridin-3-yl)-5-(5-methoxypyridin-3-yl)-1H-indole;
4-(5-(6-chloro-5-(5-methoxypyridin-3-yl)-1H-indol-2-yl)pyridin-2-yl)-1-methylpiperazin-2-one;
3'-(6-chloro-5-(5-methoxypyridin-3-yl)-1H-indol-2-yl)-1-methyl-5'H-spiro[azetidine-3,7'-furo[3,4-b]pyridine];
7-(6-chloro-5-(5-methoxypyridin-3-yl)-1H-indol-2-yl)-4-methyl-3,4-dihydro-2H-pyrido [3,2-b][1,4]oxazine;
(5-(6-chloro-5-(5-methoxypyridin-3-yl)-1H-indol-2-yl)pyridin-2-yl)(oxetan-3-yl) methanol;
6-chloro-2-(6-(methoxy(oxetan-3-yl)methyl)pyridin-3-yl)-5-(5-methoxypyridin-3-yl)-1H-indole;
2-(5-(6-chloro-5-(5-methoxypyridin-3-yl)-1H-indol-2-yl)pyridin-2-yl)propan-1-ol;
5-(6-chloro-5-(5-methoxypyridin-3-yl)-1H-indol-2-yl)-1-methylpyridin-2(1H)-one;
4-(6-chloro-5-(5-methoxypyridin-3-yl)-1H-indol-2-yl)-1-cyclopropylmethyl)pyridin-2(1H)-one;
4-(5-(7-chloro-5-(5-methoxypyridin-3-yl)-1H-indol-2-yl)pyridin-2-yl)morpholine;
4-(5-(4,6-difluoro-5-(5-methoxypyridin-3-yl)-1H-indol-2-yl)pyridin-2-yl)morpholine;
4-(5-(6-chloro-5-(quinolin-5-yl)-1H-indol-2-yl)pyridin-2-yl)morpholine;
4-(5-(6-chloro-5-(5-chloropyridin-3-yl)-1H-indol-2-yl)pyridin-2-yl)morpholine;
4-fluoro-5-(5-methoxypyridin-3-yl)-2-(2-methylpyridin-4-yl)-1H-indole;
6-fluoro-5-(5-methoxypyridin-3-yl)-2-(2-methylpyridin-4-yl)-1H-indole;
4-chloro-5-(5-methoxypyridin-3-yl)-2-(2-methylpyridin-4-yl)-1H-indole;
6-chloro-5-(5-methoxypyridin-3-yl)-2-(2-methylpyridin-4-yl)-1H-indole;
5-(5-methoxypyridin-3-yl)-4-methyl-2-(2-methylpyridin-4-yl)-1H-indole;
5-(5-methoxypyridin-3-yl)-6-methyl-2-(2-methylpyridin-4-yl)-1H-indole;

4-methyl-2,5-di(pyridin-4-yl)-1H-indole;
6-methyl-2,5-di(pyridin-4-yl)-1H-indole;
4-(5-(4-chloro-5-(5-methoxypyridin-3-yl)-1H-indol-2-yl)pyridin-2-yl)morpholine;
4-(5-(6-chloro-5-(5-methoxypyridin-3-yl)-1H-indol-2-yl)pyridin-2-yl)morpholine;
4-chloro-2,5-di(pyridin-4-yl)-1H-indole
6-chloro-2,5-di(pyridin-4-yl)-1H-indole;
N,N-dimethyl-4-(2-(2-methylpyridin-4-yl)-1H-indol-5-yl)pyridin-2-amine;
5-(6-cyclopropylpyridin-3-yl)-2-(2-methylpyridin-4-yl)-1H-indole;
5-(6-methoxypyridin-3-yl)-2-(2-methylpyridin-4-yl)-1H-indole;
5-(6-(methoxymethyl)pyridin-3-yl)-2-(2-methylpyridin-4-yl)-1H-indole;
5-(5-ethoxypyridin-3-yl)-2-(2-methylpyridin-4-yl)-1H-indole;
5-(5-cyclopropoxypyridin-3-yl)-2-(2-methylpyridin-4-yl)-1H-indole;
5-(5-(cyclopropylmethoxy)pyridin-3-yl)-2-(2-methylpyridin-4-yl)-1H-indole;
5-(5-cyclopropylpyridin-3-yl)-2-(2-methylpyridin-4-yl)-1H-indole;
7-(2-(2-methylpyridin-4-yl)-1H-indol-5-yl)-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine;
3-(2-(2-methylpyridin-4-yl)-1H-indol-5-yl)quinoline;
N-methyl-4-(2-(2-methylpyridin-4-yl)-1H-indol-5-yl)pyridin-2-amine;
4-(4-(2-(2-methylpyridin-4-yl)-1H-indol-5-yl)pyridin-2-yl)morpholine;
5-(6-chloro-2-(6-morpholinopyridin-3-yl)-1H-indol-5-yl)quinolin-2-ol;
4-(5-(6-chloro-5-(thieno[2,3-c]pyridin-4-yl)-1H-indol-2-yl)pyridin-2-yl)morpholine;
4-(5-(6-chloro-5-(6-fluoroquinolin-4-yl)-1H-indol-2-yl)pyridin-2-yl)morpholine;
4-(5-(6-chloro-5-(2-methoxyquinolin-5-yl)-1H-indol-2-yl)pyridin-2-yl)morpholine;
4-(5-(6-fluoroquinolin-4-yl)-1H-indol-2-yl)-N,N-dimethylpyridin-2-amine;
4-(5-(isoquinolin-4-yl)-1H-indol-2-yl)-N,N-dimethylpyridin-2-amine;
N,N-dimethyl-4-(5-(quinolin-5-yl)-1H-indol-2-yl)pyridin-2-amine;
3-chloro-2,5-di(pyridin-4-yl)-1H-indole;
2-(2-methylpyridin-4-yl)-5-(pyridin-4-yl)-1H-indole;
5-(5-methoxypyridin-3-yl)-2-(2-methylpyridin-4-yl)-1H-indole;
5-(5-methoxypyridin-3-yl)-2-(pyridin-4-yl)-1H-indole;
5-(5-methoxypyridin-3-yl)-2-(pyridin-3-yl)-1H-indole;
4-(2-(pyridin-4-yl)-1H-indol-5-yl)quinoline;
4-(2-(pyridin-3-yl)-1H-indol-5-yl)quinoline;
2,5-di(pyridin-4-yl)-1H-indole;
2-(pyridin-3-yl)-5-(pyridin-4-yl)-1H-indole;
2,5-di(pyridin-3-yl)-1H-indole;
2-(1-methyl-1H-pyrazol-5-yl)-5-(pyridin-4-yl)-1H-indole;
5-(2-(4-methylpiperazin-1-yl)pyridin-4-yl)-2-(pyridin-4-yl)-1H-indole;

5-(5-methoxypyridin-3-yl)-2-(pyridin-2-yl)-1H-indole;
5-(5-methoxypyridin-3-yl)-2-(pyrimidin-4-yl)-1H-indole;
2-(3-fluoropyridin-4-yl)-5-(5-methoxypyridin-3-yl)-1H-indole;
1-isopropyl-5-(5-methoxypyridin-3-yl)-2-(2-methylpyridin-4-yl)-1H-indole;
4-(5-(6-chloro-5-(5-methoxypyridin-3-yl)-1-methyl-1H-indol-2-yl)pyridin-2-yl) morpholine;
1-(2-methoxyethyl)-2,5-di(pyridin-4-yl)-1H-indole;
1-(2-methoxyethyl)-5-(5-methoxypyridin-3-yl)-2-(2-methylpyridin-4-yl)-1H-indole;
1-methyl-5-(5-methoxypyridin-3-yl)-2-(2-methylpyridin-4-yl)-1H-indole;
1-ethyl-5-(5-methoxypyridin-3-yl)-2-(2-methylpyridin-4-yl)-1H-indole;
1-(cyclopropylmethyl)-5-(5-methoxypyridin-3-yl)-2-(2-methylpyridin-4-yl)-1H-indole;
1-(benzyl)-5-(5-methoxypyridin-3-yl)-2-(2-methylpyridin-4-yl)-1H-indole;
7-(4-chloro-5-(5-methoxypyridin-3-yl)-l-methyl-1H-indol-2-yl)-4-methyl-3,4-dihydro- 2H-pyrido[3,2-b][1,4]oxazine;
7-(6-chloro-5-(5-methoxypyridin-3-yl)-l-methyl-1H-indol-2-yl)-4-methyl-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine;
1-cyclopropyl-5-(5-methoxypyridin-3-yl)-2-(2-methylpyridin-4-yl)-1H-indole;
1-methyl-2,5-di(pyridin-4-yl)-1H-indole; and
5-(5-methoxypyridin-3-yl)-2-(3-methylpyridin-4-yl)-1H-indole.

12. A NOX inhibitor for use as claimed in any one of Claims 1 to 3, wherein the NOX inhibitor is 2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione.

13. A combination product comprising:
(a) a NOX inhibitor, or a pharmaceutically-acceptable salt thereof, optionally wherein the NOX inhibitor is as defined in any one of Claims 2 to 12; and
(b) an ACE inhibitor, or a pharmaceutically-acceptable salt thereof, and/or an ARB, or a pharmaceutically-acceptable salt thereof,
for use in the treatment of Alport syndrome.

14. A combination product for use as claimed in Claim 13, which comprises a pharmaceutical formulation including a NOX inhibitor; an ACE inhibitor and/or an ARB; and a pharmaceutically-acceptable adjuvant, diluent or carrier.

15. A combination product for use as defined in Claim 13 or Claim 14, wherein the ACE inhibitor is selected from the list consisting of ramipril, benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, and trandolapril.

16. A combination product for use as defined in any one of Claims 13 to 15, wherein the combination product comprises:

(a) 2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione, or a pharmaceutically-acceptable salt thereof; and

(b) ramipril, or a pharmaceutically-acceptable salt thereof.

17. A combination product for use according to Claim 13 or Claim 14, wherein the ARB is selected from the list consisting of azilsartan, candesartan, eprosartan, sparsentan, irbesartan, losartan, Olmesartan, telmisartan and valsartan.

18. A combination product for use as claimed in any one of Claims 13 to 17, which comprises a kit of parts comprising components:

(A) a pharmaceutical formulation including a NOX inhibitor, or a pharmaceutically-acceptable salt thereof, in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier, optionally wherein the NOX inhibitor is as defined in any one of Claims 2 to 12; and

(B) a pharmaceutical formulation included an ACE inhibitor, or a pharmaceutically-acceptable salt thereof, and/or an ARB, or a pharmaceutically-acceptable salt thereof, in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier,

which components (A) and (B) are each provided in a form that is suitable for administration in conjunction with the other.

19. A kit of parts comprising:

(I) one of components (A) and (B) as defined in Claim 18; together with

(II) instructions to use that component in conjunction with the other of the two components.

20. Use of a NOX inhibitor, as defined in any one of Claims 1 to 12, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of Alport syndrome.